F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comDr Reddys Laboratories Ltd is one of India’s leading pharmaceutical companies with a strong global footprint across the US, Europe, Russia, and emerging markets. The company operates in generics, APIs (Active Pharmaceutical Ingredients), biosimilars, and specialty pharmaceuticals.
With consistent revenue growth, strong international presence, and improving margins, Dr Reddys Laboratories Ltd remains a key large-cap pharma stock in India. In this article, we analyze Dr Reddys Laboratories Ltd Share Price Target from 2026 to 2030 based on current market data, fundamentals, and long-term industry outlook.
| Detail | Value |
|---|---|
| Open | ₹1,307.50 |
| Previous Close | ₹1,307.40 |
| Day’s High | ₹1,315.00 |
| Day’s Low | ₹1,301.30 |
| VWAP | ₹1,306.97 |
| 52-Week High | ₹1,379.70 |
| 52-Week Low | ₹1,020.00 |
| All-Time High | ₹1,421.49 |
| All-Time Low | ₹43.36 |
| Market Capitalization | ₹1,08,837 Cr |
| Volume | 9,76,997 |
| Value (Lacs) | ₹12,740.04 |
| 20D Avg Volume | 12,26,672 |
| 20D Avg Delivery (%) | 58.13% |
| Face Value | ₹1 |
| Book Value Per Share | ₹431.49 |
| Dividend Yield | 0.61% |
| UC Limit | ₹1,438.10 |
| LC Limit | ₹1,176.70 |
| Beta | 0.85 |
The stock is trading close to its 52-week high, indicating strong bullish momentum in the pharma sector.
The company operates across:
Generic medicines
Branded formulations
APIs
Biosimilars
Specialty and complex injectables
Dr Reddys has strong exposure to regulated markets, especially the US, which contributes significantly to revenue. The company also invests heavily in R&D to strengthen its product pipeline.
Strong global presence across regulated markets
Diversified product portfolio
Focus on high-margin specialty products
Consistent R&D investments
Healthy institutional participation
Moderate Beta (0.85) indicating controlled volatility
| Investor Type | Holding (%) |
|---|---|
| Foreign Institutions | 33.22% |
| Promoters | 26.64% |
| Other Domestic Institutions | 16.57% |
| Mutual Funds | 13.87% |
| Retail & Others | 9.71% |
High foreign institutional ownership reflects global investor confidence in the company’s long-term growth prospects.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2026 | 1,450 | 1,600 |
| 2027 | 1,700 | 1,900 |
| 2028 | 2,000 | 2,250 |
| 2029 | 2,350 | 2,700 |
| 2030 | 2,800 | 3,200 |
These projections assume steady earnings growth, expansion in specialty segments, and stable US market performance.
Growth Drivers:
Strong US generic sales
Margin improvement
Product pipeline approvals
Investment View: Suitable for medium-term pharma investors.
Expected catalysts:
Biosimilar launches
Expansion in emerging markets
Higher operating leverage
Investment View: Attractive for long-term portfolios.
By 2028, potential drivers include:
Specialty drug expansion
R&D pipeline commercialization
Stable currency environment
Investment View: Strong compounding candidate in pharma sector.
If earnings continue growing steadily:
Improved return ratios
Higher global market share
Stronger free cash flow generation
Investment View: Balanced growth with defensive characteristics.
By 2030, the company could:
Strengthen global biosimilar presence
Expand specialty and high-margin portfolio
Deliver consistent 12–15% earnings CAGR
Valuation re-rating combined with earnings growth could support these levels.
Market Cap: ₹1.08 Lakh Crore (Large-cap pharma)
Book Value: ₹431.49
Dividend Yield: 0.61%
Beta: 0.85 (Moderate volatility)
52-Week Range: ₹1,020 – ₹1,379
The company remains fundamentally strong with solid institutional backing.
Growing global demand for generics
Biosimilar expansion
Strong US pipeline
Focus on specialty medicines
Increasing healthcare spending worldwide
US FDA regulatory risks
Pricing pressure in generics
Currency fluctuations
Patent litigations
Competition in biosimilars
Dr Reddys Laboratories Ltd is a strong large-cap pharma stock with:
Global diversification
Strong R&D focus
Healthy institutional participation
Stable business model
It is suitable for:
Long-term investors
Defensive portfolio allocations
Investors seeking pharma exposure
Moderate-risk investors
Dr Reddys Laboratories Ltd continues to demonstrate strong global presence, diversified revenue streams, and steady earnings growth. Trading near its 52-week high, the stock reflects strong investor confidence in the pharma sector.
Based on projected growth and sector outlook, the stock could potentially reach ₹2,800 to ₹3,200 by 2030, supported by biosimilar expansion, specialty drug growth, and international market stability.
Investors should monitor US regulatory developments, margin trends, and quarterly earnings before making long-term commitments.
1. What is the current share price of Dr Reddys Laboratories Ltd?
It is trading around ₹1,300–₹1,310 as per recent data.
2. What is the 2026 share price target?
The projected range is ₹1,450 to ₹1,600.
3. What is the 2030 share price target?
The estimated range is ₹2,800 to ₹3,200.
4. Does Dr Reddys Laboratories Ltd pay dividends?
Yes, the dividend yield is approximately 0.61%.
5. Is Dr Reddys Laboratories Ltd a good long-term investment?
It is considered a fundamentally strong large-cap pharma stock suitable for long-term portfolios.
Disclaimer: This article is for educational purposes only. Stock market investments are subject to risks. Please consult a certified financial advisor before investing.
Register & Login